(“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. FAQ – Utilisateurs de TMX Argent NOUVEAU. By continuing to use our service, you agree to our use of cookies. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or. This is the list of the largest public listed companies in the Drug Manufacturers—Specialty & Generic industry from Canada by market capitalization with links to their reference stock. A live webcast of Dr. By continuing to use our service, you agree to our use of cookies. With the company starting 2023 with 8,725 employees, that’s an 11. By continuing to use our service, you agree to our use of cookies. VANCOUVER, British Columbia, Nov. 66% compared to the previous year's 69. was a. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. com. Theratechnologies Inc. stockhouse. is a speaker and consultant of Theratechnologies. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. Q4 2022 consolidated revenue growth of 14. View real-time stock prices and stock quotes for a full financial overview. By Nick Paul Taylor Jul 12, 2023 8:57am. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. The firm offers its product under the brand name of. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). We also use them to share usage information with our partners. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. THTX | Complete Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. 10% most volatile stocks in CA Market. 67% from the latest price. - TH1902 Phase 1 basket trial proceeding as planned. The abstract and poster can be found on Theratechnologies’ website. Cookies are used to offer you a better browsing experience and to analyze our traffic. - October 10, 2023) - KO Gold Inc. We also use them to share usage. 9 million and US. communications@theratech. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. Marsolais’ presentation will be available through. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further. Track Theratechnologies Inc. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. We also use them to share usage. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. We also use them to share usage information with our partners. About Us | Theratechnologies Inc. Stockhouse. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. 8 million. Theratechnologies Announces 1-for-4 Reverse Stock Split. Free cash flow. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Senior Director, Communications & Corporate Affairs. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. NCU. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. Company Participants. stock news by MarketWatch. 3. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. MONTREAL, Feb. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. 69, 1. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. Clinical-stage pharmaceutical company Theralase Technologies Inc. T. MONTREAL, Aug. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. 2 million. Image source: The Motley Fool. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. Shares of Theratechnologies are up 4. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. Stockhouse. We also use them to share usage information with our partners. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. THTX earnings call for the period ending February 29, 2020. Jours fériés des marchés. Theratechnologies to Announce Financial Results for Its First Quarter 2022. The company was. However, only about 4% of the stocks on the OTC market fall into this category. The business had revenue of $27. European Headquarters. stock news by MarketWatch. TH | October 13, 2022. 10% least volatile stocks in CA Market. RESSOURCES. -based clinical sites participating in the conduct of the Phase. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. 86%. Proceeds to Be Used to Redeem All of the Outstanding 5. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. com. com. 82 million. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. FY2022 revenue. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. FY2023 revenue guidance range set between $90 million and $95 million. 40 f102M H1. 23 to a day high of $1. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH | September 5, 2023. B2Gold Declares Fourth Quarter 2023 Dividend. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. . ("Theratechnologies" or the "Company"). In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. MONTREAL, Jan. Saint-Laurent, Canada. com uses cookies on this site. - Issued and outstanding common shares to be consolidated on the basis of 1 post. 17. By continuing to use our service, you agree to our use of cookies. 514-336-7800. T. By continuing to use our service, you agree to our use of cookies. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. stock news by MarketWatch. MONTREAL, Oct. Register for your free account today at data. H. MONTREAL, Sept. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 33. MONTREAL, Oct. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. By continuing to use our service, you agree to our use of cookies. Competitors: Unknown. The financial results presented in this press release are taken from the. 54% and a negative trailing twelve-month return on equity of. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. 8 and 1. TH | September 5, 2023. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. 36 morning pop. 51 to 200 Employees. Headquarters. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. MONTREAL, Oct. TH Stock Message Board for Investors. We also use them to share usage information with our partners. P. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. This news release constitutes a “designated news release” for the purposes. sBLA for F8 formulation of tesamorelin submitted to FDA. Stockhouse. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. Marsolais will present at the H. ET. Theratechnologies Inc. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". com uses cookies on this site. Senior Director, Investor Relations. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. Stockhouse. com. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. 35 as of 10:41 a. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. Cookies are used to offer you a better browsing. THERATECHNOLOGIES INC. Stockhouse. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. By continuing to use our service, you agree to our use of cookies. BioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. ( THTX 3. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. We also use them to share. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. Theratechnologies Inc. Theratechnologies Inc. Stockhouse. MONTREAL, Aug. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. A high-level overview of Theratechnologies Inc. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. A high-level overview of Theratechnologies Inc. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Phone Number 15143319691. By continuing to use our service, you agree to our use of cookies. Investor Relations. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. We also use them to share usage. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. In 2022, THTX's revenue was 80. We also use them to share usage information with our partners. Stockhouse. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. Stockhouse. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. Theratechnologies . 1300 (+9. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. Further. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. 04) earnings per share (EPS) for the quarter. Cookies are used to offer you a better browsing experience and to analyze our traffic. 05M. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. MONTREAL, Oct. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. ET. European Headquarters. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. Investor Relations. “This is yet another major achievement for our oncology program. Learn why it. S. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. 4% annually. com uses cookies on this site. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. (TH. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 68 to a day high of $1. 38. Theratechnologies layoffs. com. Stockhouse. One reason for that is that this tier does not include penny stocks. Find the latest Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. 1-514-336-7800. com uses cookies on this site. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. L. Stockhouse. com uses cookies on this site. Share your ideas and get valuable. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. com 10/16/2023. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV. Theratechnologies Stock Price, News and Company Updates. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. TH 48% v4,15M c1. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. THERATECHNOLOGIES INC. Theratechnologies Inc. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. By continuing to use our service, you agree to our use of cookies. com. S. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Market Cap. For investor inquiries: Leah Gibson. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. D. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. When this page refreshes you will be logged in with the new address. By continuing to use our service, you agree to our use of cookies. Theratechnologies (THTX) Stock Price, News & Analysis $1. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. . 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. We currently market. By continuing to use our service, you agree to our use of cookies. 08 (+6. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. During the last trading day the stock fluctuated 12. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. : Nasdaq Theratechnologies Inc. com. - Cash, bonds and money market funds of US$22. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Their average twelve-month price target is $36. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. m. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. According to 3 analysts, the average rating for THTX stock is "Buy. Stockhouse. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. By continuing to use our service, you agree to our use of cookies. 74M. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). MONTREAL, Dec. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 71%. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. By continuing to use our service, you agree to our use of cookies. Track Theratechnologies Inc. 2% to $21. 4%. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. ir@theratech. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to. com uses cookies on this site. -986. 65 per cent to C$1. NEW YORK, Dec. Apr 14, 2020, 8:30 a. GlobeNewswire. 49) by $0.